CHIEF EXECUTIVE OFFICER
+1 949 294-0806 email@example.com
Kira has been appointed Chief Executive Officer for Reapplix in May 2021. Prior to joining Reapplix, Kira successfully introduced new wound care growth platforms as Head of Global Marketing and a member of the global management board at Urgo Medical. Under her leadership, Urgo Medical grew to become the second-largest advanced wound care company in Europe. Kira has over a decade of experience in various marketing roles in the medical device and biologics space both at Johnson & Johnson and Allergan in the US and Europe. In addition to healthcare, she has experience working in financial services at JP Morgan Chase.
Kira has an MBA from Harvard Business School and a BA in Economics and International Relations from Brown University.
CHIEF OPERATING OFFICER
+45 25 44 83 57 firstname.lastname@example.org
Carsten brings extensive experience from working in international organisations within Pharmaceutical, Medical Device and Biotech. He has an Executive MBA and a degree in Chemical Engineering and has for more than 25 years been working within Manufacturing and Supply Chain for Novo Nordisk, Dako, Exiqon and Ferrosan Medical Devices. Carsten joined Reapplix October 2021.
CHIEF SCIENTIFIC OFFICER
+45 26 71 74 47 email@example.com
Rasmus has a MSc. in biology and immunology from Copenhagen University and a graduate certificate in Biodesign from Stanford University. He is highly experienced in working with the development of in-vitro assays for the characterization of growth factor containing products. He analyzed chronic wound fluid by microarray technology at Copenhagen Wound Healing Center and Van Andel Research Institute, MI, USA. He is an experienced entrepreneur and co-founded RAM Biotech Aps in 2001 prior to his involvement with Reapplix. His exceptional skills have been a key factor in characterizing LeucoPatch® – now named 3C Patch® – and guiding the product development, clinical and product positioning activities. He is a founder of Reapplix.
MORTEN HAVE RASMUSSEN
CHIEF FINANCIAL OFFICER
+45 53 64 74 47 firstname.lastname@example.org
Morten is an executive with background in finance and audit. Professional experience includes 4 years as audit manager at KPMG C. Jespersen and more than 12 years group finance experience from companies listed on Nasdaq Copenhagen. In the period 2011-2018 he held positions as Director of Finance for the life science companies Exiqon and QIAGEN. Morten has a M.Sc in Business Economics & Auditing (Cand. Merc. Aud.) from Copenhagen Business School. Morten joined Reapplix in February 2018.
VP GLOBAL MARKETING & EUROPEAN SALES
+49 17 27 54 73 84 email@example.com
Christian has spent more than half of his 20 professional years in wound care. After graduating from law school, he joined a Johnson & Johnson trainee program and sold Ethicon’s wound care products in the Ruhr Region, Germany. This was followed by positions as Marketing Manager Germany at J&J and EMEA Marketing Director at KCI Europe. After pursuing his Executive MBA, he joined Leica Microsystems as Global Brand Director for Leica, and accounted for the global revitalization of the brand. In recent years he was Vice President European Sales & Marketing at the Israeli start-up LifeBond, where he built the European arm of the organization, and introduced the company’s first product to the European market. Christian joined Reapplix as VP Global Marketing & European Sales in December 2018.
VP OF SALES
Kevin comes to Reapplix with 27 years of Wound Care experience, building and merging sales forces in the Acute Market, Wound Care Centers, Operating Room and Long-Term Care settings. He was part of many transformational changes such as launching Enzymatic Debriding Agents into the Acute and Long-term care markets, building, and launching the Oasis skin substitute sales force into the operating room and commercializing Leaf patient monitoring system, a digital platform to reduce the incidence of pressure ulcers. In addition, to sales force leadership, he created sales force access, building both a National Accounts Department and a Strategic Accounts Department to influence a C-Suite top-down strategy.